Access Bio, Inc. engages in the research, development, and manufacture of in vitro rapid diagnostic tests, immunochemical diagnostics, biosensors, and molecular diagnostic products worldwide. The company provides Covid-19 detection kits, which are tests for assessing the current or past presence of SARS-CoV-2.; rapid diagnostic tests, suitable for preliminary diagnosis or emergency medical screening in medical facilities with limited resources; analyzers, designed to measure different chemicals and other characteristics in biological samples; and molecular diagnostic solutions used in analyzing biological markers in the genome and proteome. It offers its products under CareStart, CareUS, CareSURE, and CareGENE brand names. The company was incorporated in 2002 and is headquartered in Somerset, New Jersey.
Frequently asked questions
What sector does Access Bio Inc (950130) operate in?
Access Bio Inc belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is Access Bio Inc (950130) current stock price?
As of the latest data, Access Bio Inc stock price is ₩2,310, with a previous close of ₩2,310.
What is Access Bio Inc (950130) current market capitalization?
Access Bio Inc market cap is approximately 81.25 billion.
Does Access Bio Inc (950130) pay dividends?
No. Access Bio Inc does not pay a dividend.
What is Access Bio Inc (950130) beta (volatility) score?
Access Bio Inc has a beta of 0.293, indicating lower volatility than the overall market.
